EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis, in vitro, and in silico study of benzothiazole-based compounds as a potent anti-Alzheimer agent

Saquib Jalil, Ghulam Shabir, Aamer Saeed, Jamshed Iqbal

Molecular Diversity · 2025

DOI: 10.1007/s11030-024-10909-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Saquib Jalil und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Advanced Drug Research, Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Benzothiazoles, Alzheimer Disease, Drug Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a multifactorial neurological disorder that involves multiple enzymes in the process of developing. Conventional monotherapies provide relief, necessitating alternative multi-targeting approaches to address AD complexity. Therefore, we synthesize N-(benzo[d]thiazol-2-yl) benzamide-based compounds and tested against monoamine oxidases (MAO-A and MAO-B). In the in vitro experimental evaluation of MAO, all the compounds displayed remarkable potency, having IC50 values in the lower micromolar range. The most potent MAO-A inhibitor was (3e) with an IC50 value of 0.92 ± 0.09 μM, whereas, (3d) was the most potent inhibitor of MAO-B with an IC50 value of 0.48 ± 0.04 μM. Moreover, Enzyme kinetics studies revealed that the potent inhibitors of MAO-A and MAO-B showed competitive mode of inhibition. Furthermore, molecular docking studies were also performed to confirm the mode of inhibition and obtain an intuitive picture of potent inhibitors. It also revealed several important interactions, particularly hydrogen bonding interaction. All the newly synthesized compounds showed good ADME pharmacokinetic profile and followed Lipinski rule; these compounds represent promising hits for the development of promising lead compounds for AD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monoamine Oxidase InhibitorsBenzothiazolesAlzheimer DiseaseDrug DesignMonoamine OxidaseMolecular Docking SimulationHumansStructure-Activity RelationshipKineticsMolecular StructureComputer Simulation

Stichwörter der Autor:innen

Aroyl isothiocyanatesBenzothiazolesContemporary spectroscopic techniquesDocking studiesMonoamine oxidase MAO-A and MAO-B inhibitors

Substanzen

Monoamine Oxidase InhibitorsBenzothiazolesMonoamine Oxidase

Autor:innen und Institutionen

  • Centre for Advanced Drug Research, Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan.
  • Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan.
  • Department of Chemistry, Quaid-I-Azam University, Islamabad, 45320, Pakistan. shabirg@yahoo.com.
  • Department of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan.

Zitieren

APA

Jalil, S., Shabir, G., Saeed, A., & Iqbal, J. (2025). Design, synthesis, in vitro, and in silico study of benzothiazole-based compounds as a potent anti-Alzheimer agent. Molecular Diversity. https://doi.org/10.1007/s11030-024-10909-6

Vancouver

Jalil S, Shabir G, Saeed A, Iqbal J. Design, synthesis, in vitro, and in silico study of benzothiazole-based compounds as a potent anti-Alzheimer agent. Molecular Diversity. 2025. doi:10.1007/s11030-024-10909-6

BibTeX
@article{Jalil2025,
  author = {Jalil, Saquib and Shabir, Ghulam and Saeed, Aamer and Iqbal, Jamshed},
  title = {Design, synthesis, in vitro, and in silico study of benzothiazole-based compounds as a potent anti-Alzheimer agent},
  journal = {Molecular Diversity},
  year = {2025},
  doi = {10.1007/s11030-024-10909-6}
}
Kostenlos starten →